Franco Felizarta - AbbVie Inc | 人才画像

基本信息

浏览量：50

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 60 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study

Stefan Schneider, Gary Blick, Christina Burke,Douglas Ward,Paul Benson,Franco Felizarta, Dallas Green,Cynthia Donovan,Gavin Harper,Deanna Merrill,Aimee A. Metzner,Katie Mycock,Hannah Wallis,Jimena Patarroyo,Andrew P. Brogan,Alan Oglesby

INFECTIOUS DISEASES AND THERAPYno. 4 (2024): 891-906

引用0浏览0WOS引用

Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase when Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial

Tahilin Sanchez Karver,Miguel Pascual-Bernaldez,Alessandro Berni, Ahmed Hnoosh, Antonella Castagna,Peter Messiaen, Maria Jose Galindo Puerto,Mark Bloch,Eisuke Adachi,Gary Sinclair,Franco Felizarta,Jonathan B. Angel,Kenneth Sutton,Denise Sutherland-Phillips,Ronald D'Amico,Deanna Kerrigan

AIDS patient care and STDs（2023）

引用1浏览0WOS引用

Durability of Sustained Virological Response to Glecaprevir/pibrentasvir and Resistance Development: A Long-Term Follow-Up Study

Fred Poordad,Franco Felizarta,Betty B. Yao,J. Scott Overcash,Tarek Hassanein,Kosh Agarwal,Edward Gane,David Shaw,Michael Waters,Preethi Krishnan,Andrew Topp,Margaret Burroughs,Frederik Nevens

Liver international（2022）

引用1浏览0WOS引用

Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir plus dasabuvir ribavirin in the TOPAZ-I and TOPAZ-II trials

Fred Poordad,RuiSarmento E. Castro,Armen Asatryan,Humberto Aguilar,Patrice Cacoub,Douglas Dieterich,Rui Tato Marinho,Armando Carvalho,Asma Siddique, Yiran Bonnie Hu,Mariem Charafeddine,Mark Bondin,Nader Khan,Daniel E. Cohen,Franco Felizarta

JOURNAL OF VIRAL HEPATITISno. 5 (2020): 497-504

引用13浏览0WOS引用

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Robert S. Brown, Maria Buti,Lino Rodrigues, Vladimir Chulanov,Wan-Long Chuang,Humberto Aguilar,Gábor Horváth,Elimelech Zuckerman,Barbara Rosado Carrion,Federico Rodriguez-Perez,Petr Urbánek,Armand Abergel, Eric Cohen,Sandra S. Lovell,Gretja Schnell,Chih-Wei Lin,Jiuhong Zha,Stanley Wang,Roger Trinh,Federico J. Mensa,Margaret Burroughs,Franco Felizarta

Journal of Hepatologyno. 3 (2020): 441-449

引用0浏览0引用

Pharmacokinetics and Antiviral Activity of Cabotegravir and Rilpivirine in Cerebrospinal Fluid Following Long-Acting Injectable Administration in HIV-infected Adults

Scott L. Letendre,Anthony Mills,Debbie Hagins,Susan Swindells,Franco Felizarta,Jerome Devente,Christopher Bettacchi,Yu Lou,Susan Ford,Kenneth Sutton,Jafar Sadik Shaik,Herta Crauwels,Ronald D'Amico,Parul Patel

The journal of antimicrobial chemotherapy/Journal of antimicrobial chemotherapy（2019）

引用22浏览0WOS引用

Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy

Jason Grebely,Gregory J. Dore,Negar N. Alami,Brian Conway,John F. Dillon,Michael Gschwantler,Franco Felizarta,Christophe Hézode,Krzysztof Tomasiewicz,Linda M. Fredrick,Emily O. Dumas,Federico J. Mensa

The International journal on drug policy（2019）

引用29浏览0WOS引用

CHANGES IN INSULIN RESISTANCE OUT TO 3 YEARS AFTER SUCCESSFUL INTERFERON-FREE TREATMENT OF CHRONIC HCV INFECTION

Mario Jorge Silva,Filipe Calinas, Diogo Bento,Eric D. Crown,Wenjing Lu,Mariem Charafeddine,Armen Asatryan,Franco Felizarta,Douglas T. Dieterich,Fred Poordad,Curtis Cooper,Dominique Larrey,Daniel E. Cohen,Patrice Cacoub

HEPATOLOGY（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn